Practice

Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems

July 11th 2025

By Aislinn Antrim

Consumers and Providers Face Biosimilar Knowledge Hurdles

July 7th 2025

By Skylar Jeremias

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption and potential benefits in health care.

Adalimumab Double Take: The Unexpected Return to Reference Humira

June 30th 2025

By Skylar Jeremias

About 13% of patients who switch from Humira to an adalimumab biosimilar switch back to the originator, according to research from Truveta. However, the presented data may not tell the full story.

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25th 2025

By Skylar Jeremias

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel disease (IBD) among children and young adults.

European Data Confirm Real-World Benefits of Adalimumab Biosimilars

June 11th 2025

By Skylar Jeremias

New research highlights the efficacy and high patient satisfaction of adalimumab biosimilars in treating inflammatory diseases.

Boosting Biosimilar Use in Osteoporosis: Why HCP Education Matters

June 9th 2025

By Skylar Jeremias

The biosimilar industry faces awareness challenges among health care professionals (HCPs), which must be addressed to increase cost savings and patient access to treatments.

How State Substitution Laws Shape Insulin Biosimilar Adoption

April 15th 2025

By Skylar Jeremias

States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.

As Biosimilar Substitutions Become More Common, Education and Patient Counseling Are Paramount

March 27th 2025

By Luke Halpern

Pharmacists play an essential role in counseling patients on biosimilar substitution protocols and following state regulations regarding interchangeable medications.

Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar

March 23rd 2025

By Deana Ferreri, PhD

People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.

How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment

March 9th 2025

By Skylar Jeremias

Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?